{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T16:20:51Z","timestamp":1779294051833,"version":"3.51.4"},"reference-count":108,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:00:00Z","timestamp":1771200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:00:00Z","timestamp":1771200000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Adelaide University"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s00198-025-07786-6","type":"journal-article","created":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T11:27:44Z","timestamp":1771241264000},"page":"781-799","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Effectiveness and safety of bone protective interventions to mitigate bone loss and skeletal fractures experienced by patients with non-metastatic breast cancer: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0180-2190","authenticated-orcid":false,"given":"Micaela J.","family":"Quinn","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2356-105X","authenticated-orcid":false,"given":"Bonnie","family":"Williams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5422-3758","authenticated-orcid":false,"given":"Tania N.","family":"Crotti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0876-0031","authenticated-orcid":false,"given":"Joanne M.","family":"Bowen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,16]]},"reference":[{"issue":"1","key":"7786_CR1","first-page":"7","volume":"71","author":"RL Siegel","year":"2021","unstructured":"Siegel RL et al (2021) Cancer statistics, 2021. CA Cancer J Clin 71(1):7\u201333","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"7786_CR2","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1053\/j.seminoncol.2020.05.004","volume":"47","author":"HCF Moore","year":"2020","unstructured":"Moore HCF (2020) Breast cancer survivorship. Semin Oncol 47(4):222\u2013228","journal-title":"Semin Oncol"},{"issue":"6","key":"7786_CR3","first-page":"767","volume":"8","author":"CT Axelsen","year":"2018","unstructured":"Axelsen CT et al (2018) Bone loss during neoadjuvant\/adjuvant chemotherapy for early stage breast cancer: a retrospective cohort study. Mol Clin Oncol 8(6):767\u2013772","journal-title":"Mol Clin Oncol"},{"issue":"4","key":"7786_CR4","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s11914-013-0179-7","volume":"11","author":"P Choksi","year":"2013","unstructured":"Choksi P et al (2013) Skeletal manifestations of treatment of breast cancer. Curr Osteoporos Rep 11(4):319\u2013328","journal-title":"Curr Osteoporos Rep"},{"issue":"3","key":"7786_CR5","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1210\/jc.2007-1876","volume":"93","author":"JS Finkelstein","year":"2008","unstructured":"Finkelstein JS et al (2008) Bone mineral density changes during the menopause transition in a multiethnic cohort of women. J Clin Endocrinol Metab 93(3):861\u2013868","journal-title":"J Clin Endocrinol Metab"},{"key":"7786_CR6","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.ejca.2018.02.004","volume":"94","author":"C Wilson","year":"2018","unstructured":"Wilson C et al (2018) Adjuvant zoledronic acid reduces fractures in breast cancer patients; an AZURE (BIG 01\/04) study. Eur J Cancer 94:70\u201378","journal-title":"Eur J Cancer"},{"issue":"9992","key":"7786_CR7","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/S0140-6736(15)60995-3","volume":"386","author":"M Gnant","year":"2015","unstructured":"Gnant M et al (2015) Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet 386(9992):433\u2013443","journal-title":"Lancet"},{"issue":"5","key":"7786_CR8","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1001\/archinte.165.5.552","volume":"165","author":"Z Chen","year":"2005","unstructured":"Chen Z et al (2005) Fracture risk among breast cancer survivors: results from the Women\u2019s Health Initiative Observational Study. Arch Intern Med 165(5):552\u2013558","journal-title":"Arch Intern Med"},{"issue":"12","key":"7786_CR9","doi-asserted-by":"publisher","first-page":"2629","DOI":"10.1007\/s00198-022-06542-4","volume":"33","author":"C Ye","year":"2022","unstructured":"Ye C et al (2022) Fractures and long-term mortality in cancer patients: a population-based cohort study. Osteoporos Int 33(12):2629\u20132635","journal-title":"Osteoporos Int"},{"issue":"12","key":"7786_CR10","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1016\/j.annonc.2020.07.019","volume":"31","author":"R Coleman","year":"2020","unstructured":"Coleman R et al (2020) Bone health in cancer: ESMO clinical practice guidelines. Ann Oncol 31(12):1650\u20131663","journal-title":"Ann Oncol"},{"key":"7786_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbo.2025.100694","volume":"53","author":"P Hadji","year":"2025","unstructured":"Hadji P et al (2025) Management of aromatase inhibitor-associated bone loss (AIBL) in women with hormone-sensitive breast cancer: an updated joint position statement of the IOF, CABS, ECTS, IEG, ESCEO, IMS, and SIOG. J Bone Oncology 53:100694","journal-title":"J Bone Oncology"},{"issue":"31","key":"7786_CR12","doi-asserted-by":"publisher","first-page":"2916","DOI":"10.1200\/JCO.19.01696","volume":"37","author":"CL Shapiro","year":"2019","unstructured":"Shapiro CL et al (2019) Management of osteoporosis in survivors of adult cancers with nonmetastatic disease: ASCO clinical practice guideline. J Clin Oncol 37(31):2916\u20132946","journal-title":"J Clin Oncol"},{"key":"7786_CR13","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.maturitas.2016.10.007","volume":"95","author":"FA Tr\u00e9mollieres","year":"2017","unstructured":"Tr\u00e9mollieres FA et al (2017) Osteoporosis management in patients with breast cancer: EMAS position statement. Maturitas 95:65\u201371","journal-title":"Maturitas"},{"issue":"3","key":"7786_CR14","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1111\/cen.13735","volume":"89","author":"M Grossmann","year":"2018","unstructured":"Grossmann M et al (2018) Assessment and management of bone health in women with oestrogen receptor-positive breast cancer receiving endocrine therapy: position statement of the Endocrine Society of Australia, the Australian and New Zealand Bone & Mineral Society, the Australasian Menopause Society and the Clinical Oncology Society of Australia. Clin Endocrinol (Oxf) 89(3):280\u2013296","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"5","key":"7786_CR15","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1007\/s00198-015-3380-y","volume":"27","author":"B Aubry-Rozier","year":"2016","unstructured":"Aubry-Rozier B et al (2016) Severe spontaneous vertebral fractures after denosumab discontinuation: three case reports. Osteoporos Int 27(5):1923\u20131925","journal-title":"Osteoporos Int"},{"issue":"2","key":"7786_CR16","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1210\/jc.2016-3170","volume":"102","author":"O Lamy","year":"2017","unstructured":"Lamy O et al (2017) Severe rebound-associated vertebral fractures after denosumab discontinuation: 9 clinical cases report. J Clin Endocrinol Metab 102(2):354\u2013358","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"7786_CR17","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1007\/s00198-015-3458-6","volume":"27","author":"AW Popp","year":"2016","unstructured":"Popp AW, Zysset PK, Lippuner K (2016) Rebound-associated vertebral fractures after discontinuation of denosumab-from clinic and biomechanics. Osteoporos Int 27(5):1917\u20131921","journal-title":"Osteoporos Int"},{"issue":"4","key":"7786_CR18","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.bone.2010.11.020","volume":"48","author":"R Baron","year":"2011","unstructured":"Baron R, Ferrari S, Russell RG (2011) Denosumab and bisphosphonates: different mechanisms of action and effects. Bone 48(4):677\u2013692","journal-title":"Bone"},{"issue":"1","key":"7786_CR19","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.fshw.2016.01.001","volume":"5","author":"F Pu","year":"2016","unstructured":"Pu F, Chen N, Xue S (2016) Calcium intake, calcium homeostasis and health. Food Sci Hum Wellness 5(1):8\u201316","journal-title":"Food Sci Hum Wellness"},{"issue":"1","key":"7786_CR20","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1002\/jcb.22661","volume":"111","author":"TD Bell","year":"2010","unstructured":"Bell TD, Demay MB, Burnett-Bowie SA (2010) The biology and pathology of vitamin D control in bone. J Cell Biochem 111(1):7\u201313","journal-title":"J Cell Biochem"},{"issue":"4","key":"7786_CR21","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1093\/ageing\/29.4.301","volume":"29","author":"O Sahota","year":"2000","unstructured":"Sahota O (2000) Osteoporosis and the role of vitamin D and calcium-vitamin D deficiency, vitamin D insufficiency and vitamin D sufficiency. Age Ageing 29(4):301\u2013304","journal-title":"Age Ageing"},{"issue":"7","key":"7786_CR22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0040783","volume":"7","author":"WW Huang","year":"2012","unstructured":"Huang WW et al (2012) Zoledronic acid as an adjuvant therapy in patients with breast cancer: a systematic review and meta-analysis. PLoS ONE 7(7):e40783","journal-title":"PLoS ONE"},{"issue":"4","key":"7786_CR23","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.clbc.2012.04.003","volume":"12","author":"Y Liu","year":"2012","unstructured":"Liu Y et al (2012) Bisphosphonate use and the risk of breast cancer: a meta-analysis of published literature. Clin Breast Cancer 12(4):276\u2013281","journal-title":"Clin Breast Cancer"},{"issue":"11","key":"7786_CR24","doi-asserted-by":"publisher","first-page":"e1433","DOI":"10.1210\/clinem\/dgad247","volume":"108","author":"SF Wang","year":"2023","unstructured":"Wang SF et al (2023) The clinical benefits of antiresorptive agents in patients with primary breast cancer receiving adjuvant endocrine therapy: a systematic review with pairwise and network meta-analysis. J Clin Endocrinol Metab 108(11):e1433\u2013e1447","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"7786_CR25","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1200\/JCO.21.02647","volume":"40","author":"A Eisen","year":"2022","unstructured":"Eisen A et al (2022) Use of adjuvant bisphosphonates and other bone-modifying agents in breast cancer: ASCO-OH (CCO) guideline update. J Clin Oncol 40(7):787\u2013800","journal-title":"J Clin Oncol"},{"issue":"1","key":"7786_CR26","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1007\/s11657-023-01211-3","volume":"18","author":"K Nicolopoulos","year":"2023","unstructured":"Nicolopoulos K et al (2023) The clinical effectiveness of denosumab (Prolia\u00ae) in patients with hormone-sensitive cancer receiving endocrine therapy, compared to bisphosphonates, selective estrogen receptor modulators (SERM), and placebo: a systematic review and network meta-analysis. Arch Osteoporos 18(1):18","journal-title":"Arch Osteoporos"},{"key":"7786_CR27","doi-asserted-by":"publisher","first-page":"829875","DOI":"10.3389\/fonc.2021.829875","volume":"11","author":"A de Sire","year":"2021","unstructured":"de Sire A et al (2021) Efficacy of antiresorptive drugs on bone mineral density in post-menopausal women with early breast cancer receiving adjuvant aromatase inhibitors: a systematic review of randomized controlled trials. Front Oncol 11:829875","journal-title":"Front Oncol"},{"key":"7786_CR28","doi-asserted-by":"publisher","first-page":"625060","DOI":"10.1155\/2014\/625060","volume":"2014","author":"PP Anagha","year":"2014","unstructured":"Anagha PP, Sen S (2014) The efficacy of bisphosphonates in preventing aromatase inhibitor induced bone loss for postmenopausal women with early breast cancer: a systematic review and meta-analysis. J Oncol 2014:625060","journal-title":"J Oncol"},{"key":"7786_CR29","doi-asserted-by":"crossref","unstructured":"Tufanaru C, Munn Z, Aromataris E, Campbell J, Hopp L (2020) Chapter 3: systematic reviews of effectiveness.\u00a0JBI Manual for Evidence","DOI":"10.46658\/JBIRM-17-03"},{"key":"7786_CR30","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71","journal-title":"BMJ"},{"key":"7786_CR31","doi-asserted-by":"crossref","unstructured":"McGuinness LA,\u00a0Higgins\u00a0JPT (2020) Higgins, Risk-of-bias VISualization (robvis): an R package and Shiny web app for visualizing risk-of-bias assessments.\u00a0Research Synthesis Methods","DOI":"10.1002\/jrsm.1411"},{"issue":"1","key":"7786_CR32","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1097\/XEB.0000000000000152","volume":"17","author":"Z Munn","year":"2019","unstructured":"Munn Z et al (2019) The development of software to support multiple systematic review types: the Joanna Briggs Institute System for the Unified Management, Assessment and Review of Information (JBI SUMARI). Int J Evid Based Healthc 17(1):36\u201343","journal-title":"Int J Evid Based Healthc"},{"key":"7786_CR33","unstructured":"Drahota A, Beller E (2019) RevMan calculator. Available from:  https:\/\/training.cochrane.org\/resource\/revman-calculator"},{"issue":"8","key":"7786_CR34","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1054\/bjoc.2001.1729","volume":"84","author":"T Saarto","year":"2001","unstructured":"Saarto T et al (2001) The effect of clodronate and antioestrogens on bone loss associated with oestrogen withdrawal in postmenopausal women with breast cancer. Br J Cancer 84(8):1047\u20131051","journal-title":"Br J Cancer"},{"issue":"1","key":"7786_CR35","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s00198-014-2955-3","volume":"26","author":"M Kalder","year":"2015","unstructured":"Kalder M et al (2015) Effects of zoledronic acid versus placebo on bone mineral density and bone texture analysis assessed by the trabecular bone score in premenopausal women with breast cancer treatment-induced bone loss: results of the ProBONE II substudy. Osteoporos Int 26(1):353\u2013360","journal-title":"Osteoporos Int"},{"issue":"6","key":"7786_CR36","doi-asserted-by":"publisher","first-page":"3209","DOI":"10.1210\/jc.2004-1444","volume":"90","author":"H Fuleihan Gel","year":"2005","unstructured":"Fuleihan Gel H et al (2005) Pamidronate in the prevention of chemotherapy-induced bone loss in premenopausal women with breast cancer: a randomized controlled trial. J Clin Endocrinol Metab 90(6):3209\u20133214","journal-title":"J Clin Endocrinol Metab"},{"issue":"19","key":"7786_CR37","doi-asserted-by":"publisher","first-page":"6336","DOI":"10.1158\/1078-0432.CCR-07-5101","volume":"14","author":"JE Lester","year":"2008","unstructured":"Lester JE et al (2008) Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer. Clin Cancer Res 14(19):6336\u20136342","journal-title":"Clin Cancer Res"},{"issue":"6","key":"7786_CR38","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1200\/JCO.2009.24.5902","volume":"28","author":"C Van Poznak","year":"2010","unstructured":"Van Poznak C et al (2010) Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial. J Clin Oncol 28(6):967\u2013975","journal-title":"J Clin Oncol"},{"issue":"2","key":"7786_CR39","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1210\/jc.2009-1366","volume":"95","author":"DL Hershman","year":"2010","unstructured":"Hershman DL et al (2010) Prevention of bone loss by zoledronic acid in premenopausal women undergoing adjuvant chemotherapy persist up to one year following discontinuing treatment. J Clin Endocrinol Metab 95(2):559\u2013566","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"7786_CR40","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1007\/s00198-015-3100-7","volume":"26","author":"SL Greenspan","year":"2015","unstructured":"Greenspan SL et al (2015) Prevention of bone loss with risedronate in breast cancer survivors: a randomized, controlled clinical trial. Osteoporos Int 26(6):1857\u20131864","journal-title":"Osteoporos Int"},{"issue":"16","key":"7786_CR41","doi-asserted-by":"publisher","first-page":"2644","DOI":"10.1200\/JCO.2007.15.2967","volume":"26","author":"SL Greenspan","year":"2008","unstructured":"Greenspan SL et al (2008) Risedronate prevents bone loss in breast cancer survivors: a 2-year, randomized, double-blind, placebo-controlled clinical trial. J Clin Oncol 26(16):2644\u20132652","journal-title":"J Clin Oncol"},{"issue":"2","key":"7786_CR42","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1023\/B:BREA.0000041624.00665.4e","volume":"87","author":"L Vehmanen","year":"2004","unstructured":"Vehmanen L et al (2004) Short-term intermittent intravenous clodronate in the prevention of bone loss related to chemotherapy-induced ovarian failure. Breast Cancer Res Treat 87(2):181\u2013188","journal-title":"Breast Cancer Res Treat"},{"issue":"26","key":"7786_CR43","doi-asserted-by":"publisher","first-page":"4289","DOI":"10.1200\/JCO.2007.15.4997","volume":"26","author":"T Saarto","year":"2008","unstructured":"Saarto T et al (2008) Ten-year follow-up of 3 years of oral adjuvant clodronate therapy shows significant prevention of osteoporosis in early-stage breast cancer. J Clin Oncol 26(26):4289\u20134295","journal-title":"J Clin Oncol"},{"issue":"1","key":"7786_CR44","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s10549-010-1201-8","volume":"125","author":"JE Kim","year":"2011","unstructured":"Kim JE et al (2011) Zoledronic acid prevents bone loss in premenopausal women with early breast cancer undergoing adjuvant chemotherapy: a phase III trial of the Korean Cancer Study Group (KCSG-BR06-01). Breast Cancer Res Treat 125(1):99\u2013106","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"7786_CR45","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1507\/endocrj.EJ12-0283","volume":"60","author":"Y Rhee","year":"2013","unstructured":"Rhee Y et al (2013) Efficacy of a combined alendronate and calcitriol agent (Maxmarvil\u00ae) in Korean postmenopausal women with early breast cancer receiving aromatase inhibitor: a double-blind, randomized, placebo-controlled study. Endocr J 60(2):167\u2013172","journal-title":"Endocr J"},{"issue":"9","key":"7786_CR46","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1016\/S1470-2045(08)70204-3","volume":"9","author":"M Gnant","year":"2008","unstructured":"Gnant M et al (2008) Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol 9(9):840\u2013849","journal-title":"Lancet Oncol"},{"issue":"5","key":"7786_CR47","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1002\/cncr.26313","volume":"118","author":"AM Brufsky","year":"2012","unstructured":"Brufsky AM et al (2012) Final 5-year results of Z-FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole. Cancer 118(5):1192\u20131201","journal-title":"Cancer"},{"issue":"6","key":"7786_CR48","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1080\/00365513.2021.1929447","volume":"81","author":"K Buch-Larsen","year":"2021","unstructured":"Buch-Larsen K et al (2021) Denosumab vs. zoledronic acid treatment in post-menopausal breast cancer: a 2-year prospective observational study. Scand J Clin Lab Invest 81(6):425\u2013431","journal-title":"Scand J Clin Lab Invest"},{"issue":"2","key":"7786_CR49","doi-asserted-by":"publisher","first-page":"162","DOI":"10.4158\/EP.14.2.162","volume":"14","author":"A Cohen","year":"2008","unstructured":"Cohen A et al (2008) Prevention of bone loss after withdrawal of tamoxifen. Endocr Pract 14(2):162\u2013167","journal-title":"Endocr Pract"},{"issue":"2","key":"7786_CR50","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1093\/annonc\/mds277","volume":"24","author":"R Coleman","year":"2013","unstructured":"Coleman R et al (2013) Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results. Ann Oncol 24(2):398\u2013405","journal-title":"Ann Oncol"},{"issue":"3","key":"7786_CR51","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.bone.2007.06.004","volume":"41","author":"CB Confavreux","year":"2007","unstructured":"Confavreux CB et al (2007) Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates. Bone 41(3):346\u2013352","journal-title":"Bone"},{"issue":"3","key":"7786_CR52","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1200\/JCO.1997.15.3.955","volume":"15","author":"PD Delmas","year":"1997","unstructured":"Delmas PD et al (1997) Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study. J Clin Oncol 15(3):955\u2013962","journal-title":"J Clin Oncol"},{"issue":"7","key":"7786_CR53","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1200\/JCO.2008.19.1783","volume":"27","author":"SL Hines","year":"2009","unstructured":"Hines SL et al (2009) Phase III randomized, placebo-controlled, double-blind trial of risedronate for the prevention of bone loss in premenopausal women undergoing chemotherapy for primary breast cancer. J Clin Oncol 27(7):1047\u20131053","journal-title":"J Clin Oncol"},{"issue":"5","key":"7786_CR54","doi-asserted-by":"publisher","first-page":"e238","DOI":"10.1111\/ajco.13034","volume":"14","author":"A Hirano","year":"2018","unstructured":"Hirano A et al (2018) Long-term effect of exemestane therapy on bone mineral density supported by bisphosphonates: results of 5-year adjuvant treatment in postmenopausal women with early-stage breast cancer. Asia Pac J Clin Oncol 14(5):e238\u2013e242","journal-title":"Asia Pac J Clin Oncol"},{"key":"7786_CR55","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1186\/s40064-015-1096-2","volume":"4","author":"H Inoue","year":"2015","unstructured":"Inoue H et al (2015) The effect of anastrozole on bone mineral density during the first 5 years of adjuvant treatment in postmenopausal women with early breast cancer. Springerplus 4:303","journal-title":"Springerplus"},{"issue":"4","key":"7786_CR56","doi-asserted-by":"publisher","first-page":"118","DOI":"10.4103\/jpp.JPP_61_19","volume":"10","author":"R Kumari","year":"2019","unstructured":"Kumari R, James E, Jose WM (2019) Assessment of aromatase inhibitor-induced bone loss and appropriateness of supportive therapy in postmenopausal breast cancer patients at a tertiary care center. J Pharmacol Pharmacother 10(4):118\u2013125","journal-title":"J Pharmacol Pharmacother"},{"key":"7786_CR57","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.bone.2018.06.007","volume":"114","author":"I Kyvernitakis","year":"2018","unstructured":"Kyvernitakis I et al (2018) Prevention of breast cancer treatment-induced bone loss in premenopausal women treated with zoledronic acid: final 5-year results from the randomized, double-blind, placebo-controlled ProBONE II trial. Bone 114:109\u2013115","journal-title":"Bone"},{"issue":"3","key":"7786_CR58","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1007\/s10549-011-1728-3","volume":"130","author":"SA Lee","year":"2011","unstructured":"Lee SA et al (2011) Effects of zoledronic acid on bone mineral density during aromatase inhibitor treatment of Korean postmenopausal breast cancer patients. Breast Cancer Res Treat 130(3):863\u2013870","journal-title":"Breast Cancer Res Treat"},{"key":"7786_CR59","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.ejca.2018.12.005","volume":"108","author":"L Livi","year":"2019","unstructured":"Livi L et al (2019) Phase 2 placebo-controlled, single-blind trial to evaluate the impact of oral ibandronate on bone mineral density in osteopenic breast cancer patients receiving adjuvant aromatase inhibitors: 5-year results of the single-centre BONADIUV trial. Eur J Cancer 108:100\u2013110","journal-title":"Eur J Cancer"},{"issue":"1","key":"7786_CR60","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.clbc.2011.08.002","volume":"12","author":"A Llombart","year":"2012","unstructured":"Llombart A et al (2012) Immediate administration of zoledronic acid reduces aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer: 12-month analysis of the E-ZO-FAST trial. Clin Breast Cancer 12(1):40\u201348","journal-title":"Clin Breast Cancer"},{"issue":"4","key":"7786_CR61","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.jbo.2013.08.001","volume":"2","author":"AJ Lomax","year":"2013","unstructured":"Lomax AJ et al (2013) Prevention of aromatase inhibitor-induced bone loss with alendronate in postmenopausal women: the BATMAN Trial. J Bone Oncol 2(4):145\u2013153","journal-title":"J Bone Oncol"},{"issue":"3","key":"7786_CR62","first-page":"1219","volume":"24","author":"N Majithia","year":"2016","unstructured":"Majithia N et al (2016) Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy: a 5-year follow-up. Support Care Cancer 24(3):1219\u20131226","journal-title":"Support Care Cancer"},{"issue":"2","key":"7786_CR63","doi-asserted-by":"publisher","first-page":"R24","DOI":"10.1186\/bcr2565","volume":"12","author":"C Markopoulos","year":"2010","unstructured":"Markopoulos C et al (2010) Management of anastrozole-induced bone loss in breast cancer patients with oral risedronate: results from the ARBI prospective clinical trial. Breast Cancer Res 12(2):R24","journal-title":"Breast Cancer Res"},{"issue":"5","key":"7786_CR64","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1007\/s00223-022-01011-w","volume":"111","author":"G Mazziotti","year":"2022","unstructured":"Mazziotti G et al (2022) Real-world effectiveness of denosumab and bisphosphonates on risk of vertebral fractures in women with breast cancer undergoing treatment with aromatase inhibitors. Calcif Tissue Int 111(5):466\u2013474","journal-title":"Calcif Tissue Int"},{"key":"7786_CR65","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.bone.2018.09.010","volume":"117","author":"M Pineda-Moncus\u00ed","year":"2018","unstructured":"Pineda-Moncus\u00ed M et al (2018) Bone health evaluation one year after aromatase inhibitors completion. Bone 117:54\u201359","journal-title":"Bone"},{"issue":"9","key":"7786_CR66","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1093\/jnci\/90.9.704","volume":"90","author":"TJ Powles","year":"1998","unstructured":"Powles TJ et al (1998) Oral clodronate and reduction in loss of bone mineral density in women with operable primary breast cancer. J Natl Cancer Inst 90(9):704\u2013708","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"7786_CR67","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s10549-018-4811-1","volume":"171","author":"CA Santa-Maria","year":"2018","unstructured":"Santa-Maria CA et al (2018) A phase II study evaluating the efficacy of zoledronic acid in prevention of aromatase inhibitor-associated musculoskeletal symptoms: the ZAP trial. Breast Cancer Res Treat 171(1):121\u2013129","journal-title":"Breast Cancer Res Treat"},{"issue":"8","key":"7786_CR68","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/S1701-2163(16)30727-7","volume":"27","author":"AM Sawka","year":"2005","unstructured":"Sawka AM et al (2005) Are oral bisphosphonates effective in improving lumbar bone mineral density in breast cancer survivors with osteopenia or osteoporosis? J Obstet Gynaecol Can 27(8):759\u2013764","journal-title":"J Obstet Gynaecol Can"},{"issue":"4","key":"7786_CR69","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/s00774-011-0341-1","volume":"30","author":"G Sergi","year":"2012","unstructured":"Sergi G et al (2012) Preventive effect of risedronate on bone loss and frailty fractures in elderly women treated with anastrozole for early breast cancer. J Bone Miner Metab 30(4):461\u2013467","journal-title":"J Bone Miner Metab"},{"issue":"5","key":"7786_CR70","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.ejca.2010.11.024","volume":"47","author":"CL Shapiro","year":"2011","unstructured":"Shapiro CL et al (2011) Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: final results from CALGB trial 79809. Eur J Cancer 47(5):683\u2013689","journal-title":"Eur J Cancer"},{"key":"7786_CR71","doi-asserted-by":"publisher","first-page":"6029","DOI":"10.2147\/OTT.S115058","volume":"9","author":"S Sun","year":"2016","unstructured":"Sun S et al (2016) Preventive effect of zoledronic acid on aromatase inhibitor-associated bone loss for postmenopausal breast cancer patients receiving adjuvant letrozole. Onco Targets Ther 9:6029\u20136036","journal-title":"Onco Targets Ther"},{"issue":"3","key":"7786_CR72","first-page":"101","volume":"7","author":"KK Swenson","year":"2009","unstructured":"Swenson KK et al (2009) Effects of exercise vs bisphosphonates on bone mineral density in breast cancer patients receiving chemotherapy. J Support Oncol 7(3):101\u2013107","journal-title":"J Support Oncol"},{"issue":"2","key":"7786_CR73","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1007\/s10549-012-1973-0","volume":"133","author":"S Takahashi","year":"2012","unstructured":"Takahashi S et al (2012) Efficacy of zoledronic acid in postmenopausal Japanese women with early breast cancer receiving adjuvant letrozole: 12-month results. Breast Cancer Res Treat 133(2):685\u2013693","journal-title":"Breast Cancer Res Treat"},{"issue":"15","key":"7786_CR74","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1002\/cncr.29327","volume":"121","author":"ND Wagner-Johnston","year":"2015","unstructured":"Wagner-Johnston ND et al (2015) 5-year follow-up of a randomized controlled trial of immediate versus delayed zoledronic acid for the prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen: N03CC (Alliance) trial. Cancer 121(15):2537\u20132543","journal-title":"Cancer"},{"issue":"5","key":"7786_CR75","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1111\/j.1447-0756.2007.00634.x","volume":"33","author":"Y Yonehara","year":"2007","unstructured":"Yonehara Y et al (2007) Aromatase inhibitor-induced bone mineral loss and its prevention by bisphosphonate administration in postmenopausal breast cancer patients. J Obstet Gynaecol Res 33(5):696\u2013699","journal-title":"J Obstet Gynaecol Res"},{"issue":"1","key":"7786_CR76","doi-asserted-by":"publisher","first-page":"207","DOI":"10.3233\/BMR-210012","volume":"35","author":"D Scaturro","year":"2022","unstructured":"Scaturro D et al (2022) Early denosumab for the prevention of osteoporotic fractures in breast cancer women undergoing aromatase inhibitors: a case-control retrospective study. J Back Musculoskelet Rehabil 35(1):207\u2013212","journal-title":"J Back Musculoskelet Rehabil"},{"issue":"2","key":"7786_CR77","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1007\/s00774-020-01138-6","volume":"39","author":"Y Ouchi","year":"2021","unstructured":"Ouchi Y et al (2021) The effect of denosumab in breast cancer patients receiving adjuvant aromatase inhibitors: 36-month results. J Bone Miner Metab 39(2):224\u2013229","journal-title":"J Bone Miner Metab"},{"key":"7786_CR78","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.2147\/TCRM.S167579","volume":"14","author":"K Nakatsukasa","year":"2018","unstructured":"Nakatsukasa K et al (2018) Effect of denosumab on bone mineral density in Japanese women with osteopenia treated with aromatase inhibitors for breast cancer: subgroup analyses of a Phase II study. Ther Clin Risk Manag 14:1213\u20131218","journal-title":"Ther Clin Risk Manag"},{"issue":"8","key":"7786_CR79","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1007\/s40618-016-0606-6","volume":"40","author":"A Catalano","year":"2017","unstructured":"Catalano A et al (2017) Quantitative ultrasound and DXA measurements in aromatase inhibitor-treated breast cancer women receiving denosumab. J Endocrinol Invest 40(8):851\u2013857","journal-title":"J Endocrinol Invest"},{"issue":"30","key":"7786_CR80","doi-asserted-by":"publisher","first-page":"4875","DOI":"10.1200\/JCO.2008.16.3832","volume":"26","author":"GK Ellis","year":"2008","unstructured":"Ellis GK et al (2008) Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol 26(30):4875\u20134882","journal-title":"J Clin Oncol"},{"issue":"2","key":"7786_CR81","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s00774-018-0917-0","volume":"37","author":"K Nakatsukasa","year":"2019","unstructured":"Nakatsukasa K et al (2019) Effects of denosumab on bone mineral density in Japanese women with osteoporosis treated with aromatase inhibitors for breast cancer. J Bone Miner Metab 37(2):301\u2013306","journal-title":"J Bone Miner Metab"},{"key":"7786_CR82","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.jbo.2018.09.008","volume":"13","author":"RE Coleman","year":"2018","unstructured":"Coleman RE et al (2018) Benefits and risks of adjuvant treatment with zoledronic acid in stage II\/III breast cancer. 10 years follow-up of the AZURE randomized clinical trial (BIG 01\/04). J Bone Oncol 13:123\u2013135","journal-title":"J Bone Oncol"},{"issue":"11","key":"7786_CR83","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1093\/annonc\/mdq217","volume":"21","author":"H Eidtmann","year":"2010","unstructured":"Eidtmann H et al (2010) Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST study. Ann Oncol 21(11):2188\u20132194","journal-title":"Ann Oncol"},{"key":"7786_CR84","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00632","volume":"8","author":"V Monda","year":"2017","unstructured":"Monda V et al (2017) Improvement of bone physiology and life quality due to association of risedronate and anastrozole. Front Pharmacol 8:632","journal-title":"Front Pharmacol"},{"issue":"2","key":"7786_CR85","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.jbo.2012.06.002","volume":"1","author":"JE Lester","year":"2012","unstructured":"Lester JE et al (2012) Prevention of anastrozole induced bone loss with monthly oral ibandronate: final 5 year results from the ARIBON trial. J Bone Oncol 1(2):57\u201362","journal-title":"J Bone Oncol"},{"issue":"2","key":"7786_CR86","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1002\/jbmr.3886","volume":"35","author":"M Pineda-Moncus\u00ed","year":"2020","unstructured":"Pineda-Moncus\u00ed M et al (2020) Increased fracture risk in women treated with aromatase inhibitors versus tamoxifen: beneficial effect of bisphosphonates. J Bone Miner Res 35(2):291\u2013297","journal-title":"J Bone Miner Res"},{"issue":"1","key":"7786_CR87","doi-asserted-by":"publisher","first-page":"34","DOI":"10.3816\/CBC.2009.n.006","volume":"9","author":"AA Muslimani","year":"2009","unstructured":"Muslimani AA et al (2009) Aromatase inhibitor-related musculoskeletal symptoms: is preventing osteoporosis the key to eliminating these symptoms? Clin Breast Cancer 9(1):34\u201338","journal-title":"Clin Breast Cancer"},{"issue":"11","key":"7786_CR88","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1097\/GME.0000000000000696","volume":"23","author":"RL Drieling","year":"2016","unstructured":"Drieling RL et al (2016) Long-term oral bisphosphonate use in relation to fracture risk in postmenopausal women with breast cancer: findings from the Women\u2019s Health Initiative. Menopause 23(11):1168\u20131175","journal-title":"Menopause"},{"issue":"8","key":"7786_CR89","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1093\/annonc\/mdr600","volume":"23","author":"F Nuzzo","year":"2012","unstructured":"Nuzzo F et al (2012) Bone effect of adjuvant tamoxifen, letrozole or letrozole plus zoledronic acid in early-stage breast cancer: the randomized phase 3 HOBOE study. Ann Oncol 23(8):2027\u20132033","journal-title":"Ann Oncol"},{"issue":"3","key":"7786_CR90","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s10549-009-0332-2","volume":"117","author":"SL Hines","year":"2009","unstructured":"Hines SL et al (2009) Immediate versus delayed zoledronic acid for prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen-N03CC. Breast Cancer Res Treat 117(3):603\u2013609","journal-title":"Breast Cancer Res Treat"},{"issue":"8","key":"7786_CR91","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1001\/jamaoncol.2021.1854","volume":"7","author":"TWP Friedl","year":"2021","unstructured":"Friedl TWP et al (2021) Prognosis of patients with early breast cancer receiving 5 years vs 2 years of adjuvant bisphosphonate treatment: a phase 3 randomized clinical trial. JAMA Oncol 7(8):1149\u20131157","journal-title":"JAMA Oncol"},{"issue":"5\u20136","key":"7786_CR92","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1159\/000334456","volume":"81","author":"T Safra","year":"2011","unstructured":"Safra T et al (2011) The protective effect of zoledronic acid on bone loss in postmenopausal women with early breast cancer treated with sequential tamoxifen and letrozole: a prospective, randomized, phase II trial. Oncology 81(5\u20136):298\u2013305","journal-title":"Oncology"},{"issue":"29","key":"7786_CR93","doi-asserted-by":"publisher","first-page":"4739","DOI":"10.1200\/JCO.2008.16.4707","volume":"26","author":"DL Hershman","year":"2008","unstructured":"Hershman DL et al (2008) Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early-stage breast cancer. J Clin Oncol 26(29):4739\u20134745","journal-title":"J Clin Oncol"},{"key":"7786_CR94","doi-asserted-by":"publisher","first-page":"100226","DOI":"10.1016\/j.jbo.2019.100226","volume":"15","author":"C Wilson","year":"2019","unstructured":"Wilson C, Martin C, Winter MC (2019) Compliance and patient reported toxicity from oral adjuvant bisphosphonates in patients with early breast cancer. A cross sectional study. J Bone Oncol 15:100226","journal-title":"J Bone Oncol"},{"issue":"2","key":"7786_CR95","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s10549-011-1429-y","volume":"127","author":"R Coleman","year":"2011","unstructured":"Coleman R et al (2011) Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01\u201304) for women with stage II\/III breast cancer. Breast Cancer Res Treat 127(2):429\u2013438","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"7786_CR96","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1200\/JCO.1997.15.4.1341","volume":"15","author":"T Saarto","year":"1997","unstructured":"Saarto T et al (1997) Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: a randomized study in premenopausal breast cancer patients. J Clin Oncol 15(4):1341\u20131347","journal-title":"J Clin Oncol"},{"issue":"4","key":"7786_CR97","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1038\/bjc.1997.105","volume":"75","author":"T Saarto","year":"1997","unstructured":"Saarto T et al (1997) Clodronate improves bone mineral density in post-menopausal breast cancer patients treated with adjuvant antioestrogens. Br J Cancer 75(4):602\u2013605","journal-title":"Br J Cancer"},{"issue":"4","key":"7786_CR98","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1007\/s00198-013-2615-z","volume":"25","author":"P Hadji","year":"2014","unstructured":"Hadji P et al (2014) Effects of zoledronic acid on bone mineral density in premenopausal women receiving neoadjuvant or adjuvant therapies for HR+ breast cancer: the probone II study. Osteoporos Int 25(4):1369\u20131378","journal-title":"Osteoporos Int"},{"key":"7786_CR99","doi-asserted-by":"publisher","first-page":"100656","DOI":"10.1016\/j.jbo.2024.100656","volume":"50","author":"F Bertoldo","year":"2025","unstructured":"Bertoldo F et al (2025) Medication related osteonecrosis (MRONJ) in the management of CTIBL in breast and prostate cancer patients. Joint report by SIPMO AND SIOMMMS. J Bone Oncol 50:100656","journal-title":"J Bone Oncol"},{"issue":"6","key":"7786_CR100","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/j.ctrv.2012.03.002","volume":"38","author":"P Hadji","year":"2012","unstructured":"Hadji P et al (2012) Antiresorptive treatment options and bone health in cancer patients-safety profiles and clinical considerations. Cancer Treat Rev 38(6):815\u2013824","journal-title":"Cancer Treat Rev"},{"key":"7786_CR101","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jbo.2017.03.001","volume":"7","author":"P Hadji","year":"2017","unstructured":"Hadji P et al (2017) Management of aromatase inhibitor-associated bone loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: joint position statement of the IOF, CABS, ECTS, IEG, ESCEO IMS, and SIOG. J Bone Oncol 7:1\u201312","journal-title":"J Bone Oncol"},{"issue":"4","key":"7786_CR102","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/s41584-019-0172-3","volume":"15","author":"E Seeman","year":"2019","unstructured":"Seeman E, Martin TJ (2019) Antiresorptive and anabolic agents in the prevention and reversal of bone fragility. Nat Rev Rheumatol 15(4):225\u2013236","journal-title":"Nat Rev Rheumatol"},{"key":"7786_CR103","doi-asserted-by":"crossref","unstructured":"Ramchand SK, Ghasem-Zadeh A, Hoermann R, White S, Yeo B, Francis PA, Xu CLH, Coleman O, Shore-Lorenti C, Ebeling PR, Zajac JD, Seeman E, Grossmann M (2024) Denosumab prevents bone loss and microarchitectural deterioration in premenopausal women with breast cancer receiving estradiol suppression therapy: a randomized controlled trial. J Clin Oncol:Jco2302309","DOI":"10.1200\/JCO.23.02309"},{"issue":"1","key":"7786_CR104","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.104085","volume":"10","author":"A Gravina","year":"2025","unstructured":"Gravina A et al (2025) Ten-year update of HOBOE phase III trial comparing triptorelin plus either tamoxifen or letrozole or zoledronic acid + letrozole in premenopausal hormone receptor-positive early breast cancer patients. ESMO Open 10(1):104085","journal-title":"ESMO Open"},{"issue":"21","key":"7786_CR105","doi-asserted-by":"publisher","first-page":"2685","DOI":"10.1200\/JCO.2012.46.4792","volume":"31","author":"EJ Rathbone","year":"2013","unstructured":"Rathbone EJ et al (2013) Osteonecrosis of the jaw and oral health-related quality of life after adjuvant zoledronic acid: an adjuvant zoledronic acid to reduce recurrence trial subprotocol (BIG01\/04). J Clin Oncol 31(21):2685\u20132691","journal-title":"J Clin Oncol"},{"issue":"1","key":"7786_CR106","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s10549-011-1644-6","volume":"129","author":"AL Rastelli","year":"2011","unstructured":"Rastelli AL et al (2011) Vitamin D and aromatase inhibitor-induced musculoskeletal symptoms (AIMSS): a phase II, double-blind, placebo-controlled, randomized trial. Breast Cancer Res Treat 129(1):107\u2013116","journal-title":"Breast Cancer Res Treat"},{"key":"7786_CR107","doi-asserted-by":"publisher","first-page":"100355","DOI":"10.1016\/j.jbo.2021.100355","volume":"28","author":"K Waqas","year":"2021","unstructured":"Waqas K et al (2021) Updated guidance on the management of cancer treatment-induced bone loss (CTIBL) in pre- and postmenopausal women with early-stage breast cancer. J Bone Oncol 28:100355","journal-title":"J Bone Oncol"},{"key":"7786_CR108","unstructured":"Tsourdi E et al (2020) Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS. J Clin Endocrinol Metab"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-025-07786-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-025-07786-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-025-07786-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T16:01:49Z","timestamp":1779292909000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00198-025-07786-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,16]]},"references-count":108,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["7786"],"URL":"https:\/\/doi.org\/10.1007\/s00198-025-07786-6","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,16]]},"assertion":[{"value":"8 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human or animal participants performed by any of the authors. As a systematic review was conducted for this research, no ethical approval or informed consent was required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"None.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}